Erratum to: Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: Results of an in vitro pilot investigation (Journal of Thrombosis and Thrombolysis DOI: 10.1007/s11239-013-0979-8);Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: Results of an in vitro pilot investigation

Journal of Thrombosis and Thrombolysis

Volumn 37, Issue 2, 2014, Pages 131-138

  Rollini, Fabiana ^a   Tello Montoliu, Antonio ^a   Patel, Ronakkumar ^a   Darlington, Andrew ^a   Wilson, Ryan E ^a   Franchi, Francesco ^a   Muñiz Lozano, Ana ^a   Desai, Bhaloo ^a   Bender, Norbert ^b   Sakariassen, Kjell S ^c   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b EVOLVA SA   (Switzerland)

^c KellSa sas   (Italy)

Author keywords

Aspirin; Clopidogrel; EV 077; Platelet aggregation

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CLOPIDOGREL; COLLAGEN; EV 077; THROMBOXANE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EFFECT; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; IN VITRO STUDY; ISCHEMIC HEART DISEASE; LIGHT TRANSMITTANCE AGGREGOMETRY; LOW DRUG DOSE; MALE; MONOTHERAPY; PILOT STUDY; PLATELET AGGREGATION ASSAY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; BLOOD PLATELETS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, THROMBOXANE; TICLOPIDINE;

EID: 84894669162     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-1003-z     Document Type: Erratum

References (28)

1. Ferroni P, Basili S, Falco A, Davì G (2004) Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2:1282-1291
2. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234
3. Creager MA, Lüscher TF, Cosentino F, Beckman JA (2003) Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 108:1527-1532
4. Ferreiro JL, Angiolillo DJ (2011) Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 123:798-813
5. Rollini F, Franchi F, Muñiz-Lozano A, Angiolillo DJ (2013) Platelet function profiles in patients with diabetes mellitus. J Cardiovasc Transl Res 6:329-345
6. Daví G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C (1990) Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 322:1769-1774
7. Daví G, Patrono C (2007) Platelet activation and atherothrombosis. N Engl J Med 357:2482-2494
8. Fontana P, Alberts P, Sakariassen KS, Bounameaux H, Meyer JP, Santana Sorensen A (2011) The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin. J Thromb Haemost 9:2109-2111
9. Tello-Montoliu A, Rollini F, Desai B, Pasqualino G, Patel R, Sorensen AS, Sakariassen KS, Angiolillo DJ (2012) Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers. J Thromb Thrombolysis 34:297-299
10. Sakariassen KS, Femia EA, Daray FM, Podda GM, Razzari C, Pugliano M, Errasti AE, Armesto AR, Nowak W, Alberts P, Meyer JP, Sorensen AS, Cattaneo M, Rothlin RP (2012) EV-077 in vitro inhibits platelet aggregation in type-2 diabetics on aspirin. Thromb Res 130:746-752
11. Richardson A, Sakariassen KS, Meyer JP, Alberts P, Sorensen AS (2013) Single ascending oral dose pharmacokinetics and pharmacodynamics study of EV-077: the specific inhibitor of prostanoid- and isoprostane-induced cellular activation. Eur J Clin Pharmacol 69:459-465
12. Alberti KG, Zimmet PZ, WHO Consultation (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539-553
13. Sakariassen KS, Muggli R, Baumgartner HR (1989) Measurements of platelet interaction with components of the vessel wall in flowing blood. Methods Enzymol 169:37-70
14. Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, Zenni MM, Guzman LA, Bass TA, Costa MA (2007) A randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the OPTIMUS (optimizing anti-platelet therapy in diabetes mellitus) study. Circulation 115:708-716
15. Lancaster GA, Dodd S, Williamson PR (2004) Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract 10:307-312
16. Huang JS, Ramamurthy SK, Lin X, Le Breton GC (2004) Cell signalling through thromboxane A2 receptors. Cell Signal 16:521-533
17. Daví G, Ciabattoni G, Consoli A et al (1999) In vivo formation of 8-iso-prostaglandinF2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99:224-229
18. Santilli F, Daví G, Consoli A et al (2006) Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol 47:391-397
19. Meade EA, Smith WL, DeWitt DL (1993) Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 268:6610-6614
20. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R et al (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373:1849-1860
21. Di Chiara J, Bliden KP, Tantry US et al (2007) The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 56:3014-3019
22. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ (2002) Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 90:625-628
23. Angiolillo DJ, Bernardo E, Sabaté M, Jimenez-Quevedo P, Costa MA, Palazuelos J, Hernández-Antolin R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Guzman LA, Bass TA, Macaya C, Fernandez-Ortiz A (2007) Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 50:1541-1547
24. Nakahata N (2008) Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther 118:18-35
25. Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, de Cordoue A, Fratacci MD (2011) Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 377:2013-2022
26. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). (1994) Circulation 89:588-595
27. Neri Serneri GG, Coccheri S, Marubini E, Violi F (2004) Drug evaluation in atherosclerotic vascular disease in diabetics (DAVID) study group. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 25:1845-1852
28. Cadroy Y, Bossavy JP, Thalamas C, Sagnard L, Sakariassen K, Boneu B (2000) Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 101:2823-2828